EGFR-targeted therapy

Loredana Vecchione, Bart Jacobs, Nicola Normanno, Fortunato Ciardiello, Sabine Tejpar

Research output: Contribution to journalArticlepeer-review


Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds. By using the framework of anti-EGFR inhibitors as treatment for colorectal cancer patients, we will review the knowledge we have reached until now in improving the development of a personalized cancer therapy and we will try to indicate the future challenges this field will face in the future.

Original languageEnglish
Pages (from-to)2765-2771
Number of pages7
JournalExperimental Cell Research
Issue number19
Publication statusPublished - Nov 15 2011


  • Anti-EGFR inhibitors
  • Colorectal cancer
  • EGFR signaling
  • Molecular subgroups
  • Oncogenic dependency
  • Personalized cancer therapy

ASJC Scopus subject areas

  • Cell Biology


Dive into the research topics of 'EGFR-targeted therapy'. Together they form a unique fingerprint.

Cite this